PDE3A and diabetes mellitus: Some of the ongoing PDE targeting such as metabolic and cardiovascular diseases with PDE5 inhibitors, vascular remodelling with PDE1C and PDE3A inhibitors, and schizophrenia with PDE1 and PDE3A inhibitors, PDE7 inhibitors for inflammation, diabetes with PDE4 inhibitors and a combination of the above depend on the disease conditions [1].